Researchers have identified a new strategy to approach resistance to therapies for patients with hematologic cancers—treating the malignancies upfront with a sequence of treatments that exploit the vulnerabilities of these cancer types.
Children and young adults with Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) who have a poor prognosis may benefit from treatment with tyrosine kinase inhibitors that are already approved by the US Food and Drug Administration (FDA).
Loss of the tumor suppressor PTEN was found to be a frequent mechanism of resistance to treatment with the PI3K-alpha inhibitor BYL719 in women with breast cancer.
Researchers have identified a potential biomarker that may confer inherent resistance to enzalutamide for patients with castration-resistant prostate cancer.
Advanced melanoma patients treated with the anti–PD-1 inhibitor MK-3475 with tumors that expressed PD-L1 had higher survival rates and more robust immune responses compared with patients with tumors that did not express PD-L1.